[Past, present, and future therapeutically options in age related macular degeneration]
- PMID: 12474433
[Past, present, and future therapeutically options in age related macular degeneration]
Abstract
Age related macular degeneration is the most common cause of blindness in patients older than 65 years of age and it ranks second after diabetic retinopathy as the leading cause of blindness in the 45 to 64 years age group. Along the time, an important number of therapeutical options was developed, in association with the pathogenic hypothesis: medication, laser treatment, photodynamic therapy, surgical methods, etc. The goal of this paper is to summarize the evolution of the main therapeutical approaches in age related macular degeneration.
Similar articles
-
Treatment of subfoveal choroidal neovascularisation in age related macular degeneration: focus on clinical application of verteporfin photodynamic therapy.Br J Ophthalmol. 2001 Apr;85(4):483-95. doi: 10.1136/bjo.85.4.483. Br J Ophthalmol. 2001. PMID: 11264143 Free PMC article. Review. No abstract available.
-
[Photodynamic therapy of age-related macular degeneration].Duodecim. 2002;118(8):813-9. Duodecim. 2002. PMID: 12238196 Review. Finnish. No abstract available.
-
[New therapies for the treatment of age-related macular degeneration].J Soc Biol. 2001;195(2):115-8. J Soc Biol. 2001. PMID: 11723822 Review. French.
-
Photodynamic therapy and combination treatments.Int Ophthalmol Clin. 2007 Winter;47(1):95-115. doi: 10.1097/IIO.0b013e31802bd7cf. Int Ophthalmol Clin. 2007. PMID: 17237676 Review. No abstract available.
-
A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration.Ophthalmology. 2007 Jun;114(6):1170-8. doi: 10.1016/j.ophtha.2006.09.019. Epub 2007 Feb 23. Ophthalmology. 2007. PMID: 17320964
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous